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aldosterone- sensitive distal nephron: importance in the control of blood 
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Abstract  
 In this review, we discuss genetic evidence supporting Guyton’s hypothesis stating that 
blood pressure control is  critically depending on fluid handling by the kidney. The review is 
focused on the genetic dissection of sodium and potassium transport in the distal nephron and 
the collecting duct that are the most important sites for the control of salt and potassium balance 
by aldosterone and angiotensine II. Thanks to the study of Mendelian forms of hypertension and 
their corresponding transgenic mouse models, three main classes of diuretic receptors 
(furosemide, thiazide, amiloride) and the main components of the aldosterone- and angiotensin-
dependent signaling pathways were molecularly identified over the past 20 years. This will allow 
to design rational strategies for the treatment of hypertension and for the development of the 
next generation of diuretics. 
 
Introduction  
Hypertension is the most common disease in the human population, affecting over 1 billion 
individuals worldwide, and is one of the major treatable risk factors in cardiovascular diseases 
including stroke, myocardial infarction, heart and kidney failure. Despite the importance of 
hypertension as a cause of cardiovascular-renal disease, its pathogenesis is largely unknown. 
Four lines of evidence have verified Guyton’s 30-year old hypothesis stating that blood pressure 
(BP) is critically dependent on salt handling by the kidney: i) physiological evidence: the 
pressure-natriuresis relationship established by Guyton; ii) pharmacological evidence: the 
introduction of diuretics (thiazide) in the early 60 as first line and, for the first time, effective 
treatment of essential hypertension; iii) genetic evidence in animal experiments (rodents): 
kidney cross transplantation between hypertensive strains and their corresponding “wild type” 
strains indicated that the hypertensive phenotype always “follows the kidney” from the 
hypertensive strain; iv) genetic evidence in humans: mutations with Mendelian transmission in 
18 genes have now been identified as genes causing a salt- loosing (hypotensive) or a salt -
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retaining (hypertensive) phenotype. All genes map to the renin-angiotensin-aldosterone system 
(RAAS). Molecular and genetic approaches have begun to define the key players and molecular 
pathways determining variations in BP. The major sodium (NKCC2, NCC and ENaC) and 
potassium (ROMK) transporters are expressed in the distal nephron and are the targets for all 
of the clinically useful diuretics - furosemide/bumetanide inhibit NKCC2, thiazides inhibit NCC 
and amiloride blocks the ENaC. Importantly, molecular/genetic approaches have also begun to 
define the signalling pathways regulating and integrating these cation transporter activities and 
their roles in determining blood pressure. Aldosterone and Angiotensin II signaling pathways are 
expressed in the distal nephron and some of their components have been found to be mutated 
in some Mendelian form of human hypertension (mineralocorticoid receptor MR, the 11β−HSD2 
that protects MR from illicit occupation by cortisol, WNK1, WNK4, Cullin3, KHEL3). Several 
mouse transgenic animals (classical transgenic, knock-in and knockout) have been generated 
to validate and study the role of these key players in both renal salt handling and blood pressure 
regulation. A number of relevant and extensive reviews have been published covering different 
aspects of the genetics of hypertension in human and animal models [1-6]. In the present 
review we will discuss recent advances that have been made in this field focusing on the control 
of sodium and potassium balance along the renal distal nephron and the collecting duct that are 
tightly regulated by aldosterone and angiotensin. We will focus on experimental evidence 
obtained by genetic dissection of sodium and potassium transport along these nephron 
segments using knock out or knock in transgenic mouse models that mimick human salt 
retaining or salt loosing syndromes with an hyper- or hypotensive phenotype respectively. 
These human diseases and their corresponding animal models have defined the most 
significant steps that are limiting in the action of aldosterone and angiotensin. These limiting 
steps represent the best drug targets for the development of novel therapies specifically for the 
next generation of diuretics that remain a class of drugs of major clinical importance for the 
treatment of hypertension. 
  
Distal nephron and collecting duct: the Aldosterone- Sensitive Distal 
Nephron 
  The nephron is the functional unit of the kidney (Figure 1). In human, 180 liters of fluid is 
filtered per day  through the glomerulus (G). Around 60% will be reabsorbed in the proximal 
tubule (PCT and PST) (2), 30% in the Henle’s loop (TL and TAL) (4), 9% in the Distal 
Convoluted Tubule (DCT), the Connecting Tubule (CNT) and the Collecting Duct (CD) leaving 
1.8 liter/day of final urine. Over 90% of renal ATP is used for fluid reabsorption driven by the 
Na,K-ATPase. Sodium and potassium balance are achieved through the final regulation of 
sodium and potassium transport in the distal nephron and the collecting duct under hormonal 
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control (aldosterone, vasopressin, angiotensin, insulin, etc). DCT cells, CNT cells and CD 
principal cells are the main cells involved in hormonal regulation. Most of the fine regulation of 
sodium and potassium transport takes place in the Thick Ascending Limb (TAL) (or Distal 
Straight Tubule), the Distal Convoluted Tubule (DCT), the Connecting Tubule (CNT) that branch 
10 to 12 nephrons onto one collecting duct (CD) (Figure 2). Aldosterone is a mineralocorticoid 
hormone that plays a critical role in achieving sodium and potassium balance by controlling 
sodium reabsorption and potassium secretion in the kidney. Glucocorticoid receptor (GR) is 
ubiquitously expressed in the glomerulus, the entire nephron and in the collecting duct whereas 
the mineralocorticoid receptor (MR) is expressed in specific segments of the nephron: the Thick 
Ascending Limb (TAL), the Distal Convoluted Tubule (DCT1 and DCT2), the Connecting Tubule 
(CNT) and in the Collecting Duct (CD). Ackerman et al. [7] using highly specific antibodies 
against MR and GR showed that MR is coexpressed with GR in TAL, DCT, CNT and CD. 
Mineralocorticoid specificity is insured by the coexpression of 11β-HSD2 that metabolize cortisol 
or corticosterone in an inactive metabolite preventing the illicit occupation of MR by 
glucocorticoids. The expression of 11β-HSD2 is strong in DCT2, CNT and CD but decreases 
sharply in DCT1 and TAL. Based on the criteria of MR/11β-HSD2 coexpression, the 
Aldosterone Sensitive Distal Nephron (ASDN) (Figure 2) has been defined [8, 9] as comprising:  
the distal part of DCT (DCT2), the CNT and the CD, anatomically and developmentally distinct 
from the nephron but expressing similar regulation by aldosterone. The role of aldosterone in 
TAL is not yet well defined but it is interesting to note that the Angiotensin II receptor (AGTR1) 
expression fully overlaps that of MR suggesting that some of the synergistic action of the two 
hormones depend on the coexpression of MR and AGTR1 in TAL and downstream to the end of 
CD. Here, we will focus primarily on the role of NKCC2, NCC, ROMK, BK and ENaC on sodium 
and potassium transport and their regulatory proteins (MR/GR, 11β-HSD2, Sgk-1, Nedd 4-2, 
WNK1, WNK4, CUL3, KLHL3). 
 
Transporters   
 
Salt loosing syndromes 
Bartter syndrome 
As reviewed  by Hebert [10] and Jentsch [11] Bartter syndrome represents a group of 
autosomal recessive disorders that are characterized by markedly reduced or absent salt 
transport by the thick ascending limb of Henle. Consequently, individuals with Bartter syndrome 
exhibit renal salt wasting and lowered blood pressure, hypokalemic metabolic alkalosis and 
hypercalciuria with a variable risk of renal stones. Five genes have been associated with the 
disease (Table 1). These include i) SLC12A2, the sodium-potassium-chloride co-transporter 
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(NKCC2) (Type I Bartter) ; ii) KCNJ1, the potassium ion channel (ROMK) (Type II Bartter); iii) 
CLCNKB, the basolateral chloride ion channel (ClCKb)(Type III Bartter) ; iv) BSND barttin (Type 
IV Bartter). Barttin is a β subunit that is required for the trafficking of CLCNKB channel to the 
plasma membrane in both the thick ascending limb and the marginal cells in the scala media of 
the inner ear that secrete potassium ion-rich endolymph. Loss-of-function mutations in BSND 
thus cause Bartter syndrome with sensorineural deafness ; v) CASR a extracellular calcium ion-
sensing receptor. Gain-of-function mutations in this receptor can result in a Bartter phenotype 
(Type V Bartter) because activation of this G protein-coupled receptor inhibits salt transport in 
the thick ascending limb. As shown in Table 1, transgenic mouse models mimic Bartter 
syndrome well Type I [12], Type II [13], Type IV [14] and to some extent Type III [15].  
 
 Gitelman syndrome 
As recently reviewed by Knoers and Levtchenko [16] Gitelman’s syndrome (GS), also referred 
to as familial hypokalemia-hypomagnesemia, is characterized by hypokalemic metabolic 
alkalosis in combination with significant hypomagnesemia and low urinary calcium excretion. 
Mutations in the solute carrier family 12, member 3 gene, SLC12A3, which encodes the 
thiazide-sensitive NaCl cotransporter (NCC), are found in the majority of GS patients [16]. At 
present, more than 140 different NCC mutations throughout the whole protein have been 
identified. As shown in Table 1, the corresponding mouse model shows a mild Gitelman like 
phenotype. In a small minority of GS patients, mutations in the CLCNKB gene, encoding the 
chloride channel CLCNKB have been identified [16] but the corresponding mouse knock in 
model has not yet been engineered. This could help to understand why some mutations in 
CLCNKB generate a Bartter like phenotype while others generate a Gitelman like phenotype.  
 
PHA-1 
As reviewed by Bonny and Rossier [17] and Zennaro et al. [18] loss-of-function mutations in two 
key components of the aldosterone response, the mineralocorticoid receptor (MR) and the 
epithelial sodium channel ENaC, cause type 1 pseudohypoaldosteronism (PHA-I), a rare 
genetic disease of aldosterone resistance characterized by salt wasting, dehydration, failure to 
thrive, hyperkalemia and metabolic acidosis. The renal form of PHA-I is caused by mutations in 
MR. The phenotype tend to be milder with age [18].  The systemic form of PHA-1 is caused by 
mutations in ENaC either α or β or γ subunits. It combines a severe perinatal salt loosing 
syndrome, metabolic acidosis, life threatening hyperkalemia with a failure to clear fluid from lung 
(wet lung syndrome) [17]. As shown in Table 1, constitutive germ line inactivation of either 
α [19], β [20] or γ [20, 21] ENaC subunit  in mice causes  perinatal lethality (100% 48 h after 
birth) with a renal [19-21]  combined with a lung phenotype [19, 21]. The data indicate that there 
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is no redundancy beween any of the 3 homologous subunits of ENaC confirming in vitro 
experiments in Xenopus Laevis oocytes. The early lethality precludes any observation of the 
relative role of each subunit in adult kidney. Nephron and/or collecting duct specific promotor 
allows to conditionally inactivate any gene of interest along the nephron or the collecting duct . 
This approach allows a true « genetic dissection » of the role of ENaC α subunit along the 
ASDN. Using a HoxB7 promotor exclusively expressed in the entire collecting duct combined to 
Cre/lox technology, it was possible to delete conditionaly and efficiently the ENaC α subunit in 
this part of ASDN [22]. Surprisingly neither sodium nor potassium balance were impaired even 
when the mice were challenged with low salt or high potassium diet. The activity of ENaC in CD 
(at least in mice) is dispensable and could be compensated by other transport systems (see 
below). Interistingly, ENaC expressed in the CD plays a critical role in  lithium-induced 
nephogenic diabetes insipidus (NDI) since CD specific deletion of α ENaC fully protect against 
lithium toxicity [23]. To investigate the relative importance of ENaC-mediated sodium absorption 
in the CNT, mice lacking α ENaC in the aquaporin 2-expressing CNT and CD were generated. 
With dietary sodium restriction, these mice experienced significant weight loss, increased 
urinary sodium excretion, and hyperkalemia [24]. Plasma aldosterone levels were significantly 
elevated under both standard and sodium-restricted diets. α ENaC expression within the 
CNT/CD is crucial for sodium and potassium homeostasis and causes signs and symptoms of 
systemic PHA-1 if missing [24]. However the phenotype was relatively mild compared to the 
neonatal human or mice phenotype raising the question of the importance of DCT2 the 
remaining nephron segment still expressing ENaC under this experimental condition. Since 
ENaC is co-expressed with NCC in DCT2 under the control of the aldosterone dependent- 
signaling pathway (Figure 1), this very short segment could play a major role in achieving 
sodium and potassium balance.  Recently, it has been possible to induce gene inactivation 
along the entire nephron and the collecting duct (excluding the glomerules) using a doxycycline- 
inducible system under the control of the Pax8 promotor [25]. With this technology it was shown 
that the induction of α ENaC deletion in adult kidney causes   a severe salt loosing syndrome 
with life threatening hyperkalemia and death if not rescued by a high sodium low potassium diet 
[26] confirming the key role of DCT2 in ASDN.  
 
Salt retaining syndromes 
Liddle syndrome 
Gain-of-function mutations in ENaC β or γ subunits cause pseudoaldosteronism (Liddle's 
syndrome), a severe form of salt-sensitive hypertension, hypokalemia, metabolic alkalosis, low 
plasma renin activity and suppressed aldosterone secretion with a Mendelian autosomal 
dominant mode of transmission [1, 27]. As shown in Table 1, Pradervand et al [28] generated a 
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transgenic mouse model expressing the human mutation identified in the princeps case, i.e. the 
deletion of a C terminal regionof the β subunit (R566Stop) comprising the critical consensus  
PPXY motif that bind to the WW domains of an E3 ubiquitylation enzyme (NEDD4L or Nedd4-
2). Under normal salt diet, mice heterozygous (L/+) and homozygous (L/L) for Liddle mutation 
(L) develop normally during the first 3 months of life. In these mice, BP is not different from wild 
type despite evidence for increased sodium reabsorption in distal colon and low plasma 
aldosterone, suggesting chronic hypervolemia. Under high salt intake, the Liddle mice develop 
high BP, metabolic alkalosis, and hypokalemia accompanied by cardiac and renal hypertrophy. 
This animal model reproduces to a large extent a human form of salt-sensitive hypertension and 
establishes a causal relationship between dietary salt, a gene expressed in kidney and 
hypertension [28]. A subsequent study [29] investigated the renal sodium transport in vivo, ex 
vivo (intact perfused tubules), and in vitro (primary culture of cortical collecting ducts [CCD]) 
bringing three independent lines of evidence for the constitutive hyperactivity of ENaC in CCD 
from mice harboring the Liddle mutation. In another study [30] whole cell currents through 
epithelial Na channels (ENaCs) were measured by patch clamp of ex vivo cortical collecting 
duct (CCD) isolated from mice homozygous for the Liddle mutation (L/L) and from wild-type 
(WT) littermates. Mineralocorticoid regulation of ENaC is maintained in a mouse model of 
Liddle's syndrome and the highest currents were recorded in L/L CCD from animal kept under 
low salt diet. The increase in whole cell current was attributed to a difference in the density of 
conducting channels, in agreement with the proposed molecular and pathogenic mechanism for 
the Liddle mutation [31, 32]. 
 
Potassium channels : ROMK and BK 
As discussed above, the critical role of ROMK is underscored by mutations causing the 
antenatal Bartter Type II, one of the most severe salt loosing syndrome. Holtzclaw et al. [33] 
have recently reviewed  the physiological importance of  potassium large conductance calcium-
activated  channels (Maxi K or BK), and their potential secretory roles in flow-induced K 
secretion and in the control of blood pressure. BK channels are also fundamental to the control 
of smooth muscle tone and neuronal excitability. BK channels can be formed by two subunits: 
the pore-forming α subunit, which is the product of the KCNMA gene family , and the 
modulatory β subunit product of the KCNMB gene family. Intracellular calcium regulates the 
physical association between the α and β subunits. In the kidney the most important BK 
channels are the αβ1 heteromer expressed in the apical membrane of CNT whereas αβ4 
heteromers are predominantly expressed in intercalated cells (Figure 1). Constitutive  germ line 
inactivation of BK α subunit results in extreme aldosteronism, hypertension, and an absence of 
flow-induced potassium secretion. Inactivation of the BK β1 subunit results in decreased 
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handling of a potassium load, increased plasma potassium, mild aldosteronism and 
hypertension that is exacerbated by a high potassium diet [34, 35]. Inactivation of BK β4 subunit 
leads to insufficient potassium handling, high plasma potassium, fluid retention, but with milder 
hypertension [36]. As discussed by Holtzclaw et al. [33] BK β1 hypertension may be a 'three-hit' 
hypertension, involving a potassium secretory defect, elevated production of aldosterone, and 
increased vascular tone. To distinguish between these three factors (adrenal, vessels, kidney), 
inducible nephron specific deletion of α1 or  β1 or β4 genes will be highly informative. 
We have considered so far the transporters (NKCC2, ROMK,  BK, NCC and ENaC)  whose role 
in sodium and potassium balance is well established. In most ASDN model little attention is paid 
to the role of intercalated cells classically involved in pH homeostasis and acid-base regulation. 
As reviewed by Eladari and Hubner [37] and Wall and Pech [38, 39], recent data, however 
indicate, that a more integrative view of the role of intercalated and principal cells along the CD 
and the CNT should be proposed.  
 
Chloride transporters : SLC26A4(pendrin) and SLC4A8 
As discussed above, the critical role of the chloride channel CLCNKB and its associated subunit 
(BDSN/ barttin) are underscored by mutations causing  Bartter Type 3 and Type 4. We will now 
discuss the role of two exchangers expressed in intercalated cells that play a role in blood 
pressure control. The protein encoded by SLC4A8 is a membrane protein that functions to 
transport sodium and bicarbonate ions across the cell membrane. Leviel et al. [40]  
demonstrated that besides the classic electrogenic amiloride-sensitive, ENaC dependent- 
sodium transport,  much of the sodium absorption in the CCD was actually amiloride- insensitive 
but thiazide- sensitive. The authors demonstrated the presence of an electroneutral, amiloride-
resistant, thiazide-sensitive, transepithelial NaCl absorption in mouse CCDs, which persists 
even with genetic disruption of ENaC [40]. The data suggested that the parallel action of the 
sodium-driven chloride/bicarbonate exchanger (NDCBE/SLC4A8) and the sodium-independent 
chloride/bicarbonate exchanger (pendrin/SLC26A4) accounted for the electroneutral thiazide-
sensitive sodium transport. Further evidence for the importance of this novel electroneutral 
transport was obtained by genetic ablation of SLC4A8 that fully abolished thiazide-sensitive 
NaCl transport in the CCD. SLC26A4 (solute carrier family 26, member 4) or pendrin is a 
membrane protein that functions as chloride/ bicabonate exchanger and mutations in this gene 
are associated with Pendred syndrome, the most common form of syndromic deafness, an 
autosomal-recessive disease. The role of  SLC26A4/pendrin in the regulation of extracellular 
fluid volume and blood pressure has recently been reviewed [39, 41]. Royaux et al. reported 
that Slc26a4 (-/-) mice were severely impaired in their renal bicarbonate secretion [42]. Next it 
was shown that a renal phenotype could become unmasked by challenging Slc26a4 (-/-) mice 
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with the mineralocorticoid DOCP. Mice devoid of pendrin develop metabolic acidosis and 
isolated CCD tubule and were unable to secrete bicarbonate. Interestingly these mice were 
« resistant » to DOCP and did not develop salt retention and hypertension was prevented [43] . 
Conversely, under salt restriction, Wall et al. reported that Slc26a4 is upregulated and is critical 
in the maintenance of acid-base balance and in the renal conservation of Cl- and water [44].   
 
Aldosterone and Angiotensin signalling pathways 
 
NKCC2 regulation 
As recently reviewed by Ares et al. [51], NKCC2 dependent-sodium chloride reabsorption in 
TAL is subject to exquisite control by hormones like vasopressin, parathyroid, glucagon, and 
adrenergic agonists that stimulate NaCl reabsorption. Atrial natriuretic peptides or autacoids like 
nitric oxide and prostaglandins (PGE2) inhibit NaCl reabsorption, promoting salt excretion. At 
least, three molecular mechanisms : membrane trafficking, phosphorylation, and protein-protein 
interactions have recently been described as mechanisms that modulate NKCC2 activity in 
TALs and heterologous expression systems [51].  
According to NCBI, SORL1 (SORLA) encodes a mosaic protein that belongs to at least two 
families: the vacuolar protein sorting 10 (VPS10) domain-containing receptor family, and the low 
density lipoprotein receptor (LDLR) family. In this context, a recent study [52] (Table 2) shows 
that the mouse Sorl1 (sorting protein-related receptor with A-type repeats) plays an important 
role in functional activation of NKCC2. Sorl1-/-  mice are unable to interact with SPAK (Ste-20-
related proline-alanine-rich kinase) that normally allows the proper trafficking of Spak to the 
apical membrane of TAL cell and the NKCC2 phosphorylation. The phenotype of the Sorl-/- 
mice is a salt losing syndrome mimicking a Bartter syndrome Type 1 indicating that this protein 
is one of the limiting factor in this signaling pathway [52]. Until now, no human SORL1 
mutations have been described. 
As reviewed by Breyer and Breyer [53],  prostaglandin PGE(2) is a major renal cyclooxygenase 
metabolite of arachidonate and interacts with four G protein-coupled E-prostanoid receptors 
designated EP(1), EP(2), EP(3), and EP(4). Through these receptors, PGE(2) modulates renal 
hemodynamics and salt and water excretion. The authors propose that the capacity of PGE(2) 
to bidirectionally modulate vascular tone and epithelial transport via constrictor EP(1) and EP(3) 
receptors versus dilator EP(2) and EP(4) receptors allows PGE(2) to serve as a buffer, 
preventing excessive responses to physiological perturbations. Along this line of thought [54, 
55], it has been shown that gene inactivation of the EP(2) receptor lead to a salt sensitive 
hypertensive phenotype. EP2-/- mice develop normally and have slightly elevated baseline 
systolic blood pressure. In EP2-/- mice, the characteristic hypotensive effect of intravenous 
PGE2 infusion was absent; PGE2 infusion instead produced hypertension. When fed a high salt 
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diet, the EP2-/- mice developed profound systolic hypertension, whereas wild-type mice showed 
no change in systolic blood pressure [54]. In another study however, a reduced blood pressure 
phenotype was observed [55]. The reason for this discrepancy remains unclear. 
 
ASDN and RAAS 
The role of the Renin Angiotensin Aldosterone System (RAAS) has been extensively reviewed 
and the role of each of its component studied by establishment of transgenic mouse models for 
renin, angiotensinogen, ACE, angiotensin II receptor, aldosterone synthase [3-5, 56]. In the 
context of the present review, a few important references will be outlined : 
Renin  
As reviewed by Corvol et al. [3] there are important differences between human and mouse 
RAAS. For instance human have one renin gene (REN) wheras some mouse strains (i.e 
C56BL6) have one copy of renin gene (Ren1c) and others (i.e SV129) have two (Ren1d and 
Ren2). Deletion of Ren2 does not modify BP [57] whereas deletion of Ren 1d decrease BP in 
heterozygote and homozygote females but not in males [58]. In mice, inactivation of any of the 
components of the renin-angiotensin system (i.e. renin, angiotensin-converting enzyme, 
angiotensinogen and AT1 receptor) is dispensable for survival at birth. Animals can survive 
although they are more sensitive to salt depletion than the wild type mice. By contrast, Renal 
Tubular Dysgenesis (RTD) is a human disease consisting of severe abnormalities of renal 
tubular development and resulting in profound anuria and perinatal death. Familial RTD is an 
autosomal recessive disease due to genetic defects in any of the constituents of the renin 
system [3]. Complete gene inactivation of the renin system in RTD leads to neonatal anuria and 
death. Proximal tubules are almost absent; renal artery hyperplasia is found in all cases of RTD. 
An intense stimulation of renin gene expression is noted in the kidney of patients with mutations 
affecting angiotensinogen, angiotensin-converting enzyme and AT1 receptor. The more severe 
phenotype in humans compared to mice devoid of a functional renin system may be attributable 
to the difference in nephrogenesis between mice and humans. In mice, nephrogenesis is 
completed 2 weeks after birth, whereas in humans it is completed before birth, at 38 weeks of 
gestation [3].  
Angiotensinogen 
As reviewed by Takahashi [59] and Smithies [5],  potentially causative variations associated 
with quantitative differences in the expression of the angiotensinogen gene (AGT) have been 
identified. Experiments to directly test causation are possible in mice is possible,  establishing 
that blood pressures are indeed altered by genetic changes in AGT expression (gene disruption 
« zero copy », heterozygous mutants « one copy », wild type « two copies », gene titration by 
gene duplication « 3 to 4 copies ». Thus, angiotensinogen-deficient mice generated by 
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homologous recombination in mouse embryonic stem cells do not produce angiotensinogen in 
the liver, resulting in the complete loss of plasma immunoreactive angiotensin I. The systolic 
blood pressure of the homozygous mutant mice is drastically reduced by >30% [60]. Gene 
titration experiment show that blood pressure rises linearly as the number of copies of the Agt 
gene increases [61]. 
 Angiotensin Converting Enzyme (ACE) 
Angiotensin-converting enzyme (ACE) is a dipeptidyl carboxy-peptidase that generates the 
vasoconstricting peptide angiotensin II and inactivates the vasodilating peptide bradykinin. The 
gene encoding ACE is composed of two homologous regions and codes for both a somatic and 
testis isoenzyme. The role of the Ace gene in blood pressure control and reproduction was 
investigated using mice generated to carry an insertional mutation that was designed to 
inactivate both forms of Ace [62]. When the Ace gene was disrupted, the BP of heterozygote 
was normal in males and lower in females despite a equal reduction of 50% of plasma enzyme 
activity in both gender. When the Ace gene was duplicated with a corresponding linear increase 
in ACE activity, there was no change in BP [62].  
Angiotensin II receptor (AGTR1) 
Angiotensin II receptors (AGTR)  are expressed in tissue compartments involved in blood 
pressure control (heart,kidney, blood vessels, adrenal glands and brain) [63]. Stimulation of 
AGTR by Angiotensin II causes potent vasoconstriction, release of aldosterone by the adrenal 
gland in turn promoting sodium absorption in ASDN [63]. In the brain Angiotensin II triggers a 
dramatic hypertensive response while in the kidney it triggers renal vasoconstriction and 
antinatriuresis. A first study showed that pressor responses to infused angiotensin II were 
virtually absent in Agtr1a(-/-) mice and were qualitatively altered in Agtr1a(+/-) heterozygotes. 
This study demonstrated clearly that mouse type 1A angiotensin II receptor function is required 
for vascular and hemodynamic responses to angiotensin II and that altered expression of the 
Agtr1a gene has marked effects on blood pressures [64]. In order to distinguish the 
physiological role of AGTR in individual tissue compartment, the authors designed an elegant 
experimental approach i.e a kidney cross transplantation strategy [63, 65]. Although actions of 
the RAAS in a variety of target organs have the potential to promote high blood pressure and 
end-organ damage, the authors showed convincingly that angiotensin II caused hypertension 
primarily through effects on AGTR1 receptors in the kidney [65]. Importantly renal AGTR1 
receptors were absolutely required for the development of angiotensin II-dependent 
hypertension and cardiac hypertrophy [65]. When AGTR1 receptors were eliminated from the 
kidney, the residual repertoire of systemic, extrarenal AGTR1 receptors was not sufficient to 
induce hypertension or cardiac hypertrophy [65]. Recently RAS actions in the epithelium of the 
proximal tubule were shown to have a critical and non redundant role in determining the level of 
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BP [66]. Abrogation of Agtr1 angiotensin receptor signaling in the proximal tubule alone is 
sufficient to lower BP, despite intact vascular responses. Elimination of this pathway reduces 
proximal fluid reabsorption and alters expression of key sodium transporters, modifying 
pressure-natriuresis and providing substantial protection against hypertension [66]. 
 
ASDN and NCC 
 WNK4 
PHAII (or Familial hyperkalemic hypertension (FHHt) or Gordon Syndrome) is a Mendelian form 
of arterial hypertension that is partially explained by mutations in WNK1 and WNK4 that lead to 
increased activity of NCC in the distal nephron [67]. PHAII is characterized by salt-, thiazide- 
sensitive hypertension, variable degree of hyperkalemia and metabolic acidosis. The 
transmission is autosomal dominant with an important genetic heterogeneity (4 genes 
identified). To study the pathophysiological mechanisms underlying the human phenotype 
caused by WNK4 mutations, WNK4 hypomorphic mice were generated by deleting exon 7 of 
the Wnk4 gene [68]. These mice did not show hypokalemia and metabolic alkalosis, but they 
did exhibit low blood pressure and increased sodium and potassium excretion under low-salt 
diet. Phosphorylation of OSR1/SPAK and NCC was significantly reduced in the mutant mice as 
compared with their wild-type littermates. Protein levels of ROMK and Maxi K (BK) were not 
changed, but ENaC appeared to be activated as a compensatory mechanism for the reduced 
NCC function [68]. Mutations in the gene encoding the kinase WNK4 cause 
pseudohypoaldosteronism type II (PHAII), a syndrome featuring hypertension and hyperkalemia 
[67]. Physiology in mice transgenic for genomic segments harboring wild-type (WT) or PHAII 
mutant WNK4 is changed in opposite directions [69]: PHAII mice have higher blood pressure, 
hyperkalemia, hypercalciuria and marked hyperplasia of the distal convoluted tubule (DCT), 
whereas the opposite is true in wild type mice. Genetic deficiency for the sodium chloride 
cotransporter of the DCT (NCC) reverses phenotypes seen in PHAII mice, demonstrating that 
the effects of the PHAII mutation are due to altered NCC activity [69]. To mimic more precisely 
the molecular pathophysiology of human PHAII in mice, Wnk4(D561A/+) knockin mice were 
generated [70]. The knockin PHAII mice showed increased apical expression of phosphorylated 
Na-Cl cotransporter (NCC) in the distal convoluted tubules. Increased phosphorylation of the 
kinases OSR1 and SPAK was also observed in the knockin mice. Apical localization of the 
ROMK and transepithelial chloride permeability in the cortical collecting ducts were not affected 
in the knockin mice, whereas activity of ENaC was increased. This increase, however, was not 
evident after hydrochlorothiazide treatment, suggesting that the regulation of ENaC was not a 
genetic but a secondary effect [70].  Overall these two studies nicely establish mouse models to 
study the molecular physiopathology of PHAII or Gordon syndrome. Small differences between 
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the two studies are probably due to the different methodological approach (bac transgene vs 
knock in). 
STK39  (SPAK) 
Serine Threonine kinase 39 (STK39) or Ste20-like proline/alanine-rich kinase (SPAK) encodes 
a serine/threonine kinase that is thought to function in the cellular stress response pathway. 
STK39/SPAK interacts with WNK kinases to regulate NKCC2 and NCC. SPAK-null mice were 
generated by targeting disruption of exons 9 and 10 of SPAK. Compared with SPAK(+/+) 
littermates, SPAK(+/-) mice exhibited hypotension without significant electrolyte abnormalities, 
and SPAK(-/-) mice not only exhibited hypotension but also recapitulated Gitelman syndrome 
with hypokalemia, hypomagnesemia, and hypocalciuria [71]. To define the importance of the 
WNK/SPAK in regulating blood pressure, knock-in mice in which SPAK cannot be activated by 
WNKs were generated [72]. The SPAK knock-in animals are viable, but display significantly 
reduced blood pressure that was salt-dependent. These animals also have markedly reduced 
phosphorylation of NCC and NKCC2 cotransporters at the residues phosphorylated by SPAK. 
This was also accompanied by a reduction in the expression of NCC and NKCC2 protein 
without changes in mRNA levels. On a normal sodium diet, the SPAK knock-in mice were 
normokalaemic, but developed mild hypokalemia when the renin-angiotensin system was 
activated by a low sodium diet [72]. 
WNK1 
As reviewed by Bergaya et al. [73],  the WNK1 gene gives rise to a ubiquitous kinase (L-WNK1) 
and to a shorter kinase-defective isoform, KS-WNK1 (for kidney-specific WNK1), expressed 
only in the distal convoluted tubule (DCT) and connecting tubule (CNT) (see Figure 1). WNK1 
first intron deletion leads to overexpression of L-WNK1 in the DCT and ubiquitous ectopic 
expression of KS-WNK1. The increased expression of L-WNK1 in the DCT results in increased 
activity of the Na-Cl cotransporter (NCC) and thus hypervolemia and hypertension. The 
mechanisms underlying the hyperkalemia and metabolic acidosis remain unclear [73]. 
Hadchouel et al. [74] inactivated KS-WNK1 expressed only in DCT (Figure 1) and showed that 
this isoform is an important regulator of sodium transport. KS-WNK1(-/-) mice display an 
increased activity of NCC, expressed specifically in the distal convoluted tubule, where it 
participates in the fine tuning of sodium reabsorption [74]. The authors suggest that the 
activation of NCC is not sufficient by itself to induce a hyperkalemic hypertension and that the 
deregulation of other channels, such as ENaC, is probably required [74]. In another study Liu et 
al. [75] came to similar conclusions 
KLHL3 and CULLIN 
 Recently two studies using exome sequencing  identified mutations in Kelch-like 3 (KLHL3) [76, 
77] or CULLIN3 (CUL3) [76] in PHAII patients. KLHL3 mutations are either recessive or 
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dominant, whereas CUL3 mutations are dominant and predominantly de novo. CUL3 and BTB-
domain-containing kelch proteins such as KLHL3 are components of CULLIN -RING E3 ligase 
complexes that ubiquitylate substrates bound to kelch propeller domains. Dominant KLHL3 
mutations are clustered in short segments within the kelch propeller and BTB domains 
implicated in substrate and cullin binding respectively [76]. Polymorphisms at KLHL3 were not 
associated with blood pressure [77]. KLHL3 is coexpressed with NCC and downregulates NCC 
expression at the cell surface [77]. Both studies establishes a role for KLHL3-CUL3 as new 
members of the complex signaling pathway regulating ion homeostasis in the distal nephron 
and indirectly blood pressure [77]. Three publications have recently identified WNK4 as a major 
substrate of the KLHL3-CUL3 complex [78-80]. Collectively, the data demonstrate that CUL3-
RING ligases that contain KLHL3 target ubiquitylation of WNK4 regulate WNK4 levels, which in 
turn regulate levels of ROMK. 
 
ASDN and ENaC 
MR and GR 
Mineralocorticoid receptor (MR)-deficient mice have a normal prenatal development but die 
within 10 days after birth from a salt-losing syndrome mimicking human PHA 1 [81]. Interistingly 
this phenotype could be rescued by subcutaneous infusion of saline and this treatment enables 
the animals to develop through this critical phase of life, after which they adapt their oral salt 
and water intake to match the elevated excretion rate. However, the renal salt-losing defect 
persists [82]. Due to the obvious experimental limitations of germline inactivation of MR, 
Ronzaud et al. [83]  generated mice with MR deficiency in principal cell using the Cre-loxP 
system driven by regulatory elements of the mouse aquaporin 2 (AQP2) promotor. This strategy 
should inactivate MR in the late portion of CNT and CD (Figure 2). The authors demonstrated 
that inactivation of MR in CD and late CNT can be compensated under standard diet but no 
longer when sodium supply is limited. Because the mutant mice show preserved renal ENaC 
activity, this study provides evidence that the late distal convoluted tubule and early CNT can 
compensate to a large extent deficient ENaC-mediated sodium reabsorption in late CNT and 
CD [83]. Since AQP2 is already expressed during renal development, MR ablation took place 
long before the analysis performed at the adult stage leving open the possibility of non defined  
long term compensatory mechanisms. To investigate whether the early onset of MR ablation 
affected the adult renal sodium handling,  Ronzaud et al. [84] have recently used a inducible 
somatic gene inactivation strategy by developing a transgene expressing the CreER(T2) fusion 
protein under control of the regulatory elements of the AQP2 gene (AQP2CreER(T2)). Under a 
low-salt diet and at adult stage, the induced ablation of MR at the adult stage recapitulates the 
renal sodium wasting observed in mice with constitutive early-onset MR ablation [84]. In human, 
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a S810L mutation in the mineralocorticoid receptor (MR) causes early-onset hypertension that is 
markedly exacerbated in pregnancy as described by Geller et al. [85]. This mutation results in 
constitutive MR activity and alters receptor specificity, with progesterone and other steroids 
lacking 21-hydroxyl groups, normally as MR antagonists, becoming potent agonists [85]. To our 
knowledge, no mouse knock in model have been developed to mimick this highly interesting 
pathophysiological situation. 
Experiments in Cushing patients and healthy control subjects receiving 
adrenocorticotropic hormone (ACTH) indicate that transient renal sodium retention may 
contribute to the generation of hypertension [86]. Bailey et al. [86] have investigated the effect of 
chronic ACTH infusion on renal sodium handling in adult male C57BL/6J mice using selective 
antagonists to dissect mineralocorticoid and glucocorticoid receptor-mediated pathways. ACTH 
caused an increase in blood pressure and a reduction in fractional sodium excretion associated 
with enhanced activity of ENaC. ACTH excess promotes renal sodium reabsorption, 
contributing to the increased blood pressure; both glucocorticoid and mineralocorticoid receptor 
pathways are involved. These in vivo data are interesting and relevant to the relative occupancy 
of MR vs GR by aldosterone and cortisol that is controlled by 11β-HSD2. In vitro studies 
indicate that aldosterone occupies both MR and GR under physiological conditions to mediate 
the sodium transport response but cortisol or corticosterone may also occupy MR and GR under 
extreme stress [87].  
HSD11B2 (11β-HSD2) 
HSD11B2 (11β-HydroxySteroidDehydrogenase Type 2 = 11β HSD2) controls ligand access to 
the mineralocorticoid receptor, and ablation (or inhibition by drug or toxic) of the enzyme causes 
severe hypertension in human (Apparent Mineralocorticoid Excess =AME) [88]. Bailey et al. [89] 
generated a Hsd11b2 null mouse on an inbred C57BL/6J genetic background, allowing survival 
to adulthood. Initially, impaired sodium excretion associated with increased activity of the 
epithelial sodium channel was observed. Later KO mice had BP approximately 20 mmHg higher 
on average compared with wild-type mice but were volume contracted, not volume expanded as 
expected. Volume contraction was not attributable to intrinsic vascular dysfunction but rather to 
high catecholamine levels, an important pathogenic factor since alpha1-adrenergic receptor 
blockade rescued the hypertensive phenotype, suggesting that vasoconstriction contributes to 
the sustained hypertension in this model. It was proposed that renal sodium retention remains a 
key event in apparent mineralocorticoid excess but that the accompanying hypertension 
changes from a renal to a vascular etiology over time [89]. In a subsequent study Bailey et al. 
[90] used mice heterozygote for a null mutation in Hsd11b2 to define the mechanisms linking 
reduced enzyme activity to salt sensitivity of blood pressure. A high-sodium diet caused a rapid 
and sustained increase in blood pressure in heterozygote mice (leading to increased heart 
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weight) but not in wild-type littermates. Interistingly, mineralocorticoid receptor antagonism 
partially prevented the increase in heart weight but not the increase in blood pressure. 
Glucocorticoid receptor antagonism prevented the rise in blood pressure suggesting a novel 
interaction among 11β-HSD2, dietary salt, and circulating glucocorticoids [90]. 
SGK1 
The serum- glucocorticoid induced-kinase 1 (SGK1) belongs to the superfamily of AGC protein 
kinase [91]. Sgk1 is an early aldosterone- induced gene (see review in ref [92, 93]). No 
Mendelian form of human salt-losing or salt retainig syndromes have been mapped to mutations 
of the SGK1 gene. However, the physiological role of Sgk1 has been extensively studied in 
mouse models in vitro and in vivo. Wullf et al. [94] showed that under a standard NaCl intake, 
renal water and electrolyte excretion was indistinguishable between Sgk1(-/-) mice and wild-
type mice. In contrast, dietary NaCl restriction reveals an impaired ability of Sgk1(-/-) mice to 
adequately decrease sodium excretion despite increases in plasma aldosterone levels and 
proximal-tubular sodium and fluid reabsorption, as well as decreases in blood pressure and 
glomerular filtration rate. Overall a mild PHA-1 phenotype was observed. In a second study, 
Huang et al. [95] studied the importance of Sgk1 in renal elimination of potassium. 
Electrophysiological and immunohistochemical studies under high potassium diet indicated that 
reduced epithelial sodium channel ENaC and/or Na,K-ATPase activity in the aldosterone-
sensitive distal nephron accounted for the impaired response in Sgk1-/- and that an enhanced 
apical abundance of renal outer medullary potassium channel ROMK partly compensated for 
the defect.  The authors concluded that the acute and chronic regulation of renal potassium 
elimination involves Sgk1. Vallon et al. [96] studied the contribution of Sgk1 to the regulation of 
renal function, salt intake, and blood pressure during DOCA-salt excess in Sgk1 deficient mice. 
There was no difference in DOCA salt induced increased blood pressure and in creatinine 
clearance. A more pronounced increase of proteinuria in Sgk1(-/-) mice was observed. Overall 
the observed phenotype was mild and the authors concluded that SGK1 contributes to the 
stimulation of salt intake, kidney growth, proteinuria, and renal potassium excretion during 
mineralocorticoid excess [96]. More recently, Faresse et al. [97] used a somatic nephron 
specific inducible gene deletion strategy to study the role of renal nephron specific Sgk1 in adult 
kidney. Under a standard sodium diet, renal water and Na/K excretion had a tendency to be 
higher in doxycycline-treated Sgk1 KO mice compared with control mice. The impaired ability of 
Sgk1 KO mice to retain Na increased significantly with a low-salt diet despite higher plasma 
aldosterone levels. On a low sodium diet, the Sgk1 KO mice were also hyperkaliuric and lost 
body weight. This phenotype was accompanied by a decrease in systolic and diastolic blood 
pressure. This phenotype mimics a mild human PHA-1 phenotype indicating that Sgk1 is, to 
some extent, limiting in the action of aldosterone in ASDN. In another study, Fejes-Toth et al. 
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[98] also showed a mild salt-losing phenotype under salt restriction and concluded  that SGK1 
was essential for optimal processing of ENaC but was not required for activation of the channel 
by aldosterone [98]. 
 NEDD4L (Nedd4-2) 
NEDD4L encodes a member of the Nedd4 family of HECT domain E3 ubiquitin ligases. HECT 
domain E3 ubiquitin ligases transfer ubiquitin from E2 ubiquitin-conjugating enzymes to protein 
substrates, thus targeting specific proteins for lysosomal degradation. The encoded protein 
mediates the ubiquitylation of multiple target substrates and plays a critical role in epithelial 
sodium transport by regulating the cell surface expression of the epithelial sodium channel, 
ENaC [32]. Single nucleotide polymorphisms in this gene may be associated with essential 
hypertension [32]. Shi et al. [99] generated Nedd4-2 null mice. The knockout mice had higher 
BP on a normal diet and a further increase in BP when on a high-salt diet. Overall, the authors 
concluded that in vivo Nedd4-2 is a critical regulator of ENaC activity and BP. The absence of 
this gene is sufficient to produce salt-sensitive amiloride sensitive hypertension mimicking 
Liddle syndrome[99]. This data are consistent with a genetic interaction between ENaC β or γ 
subunit and Nedd4-2, in turn, in agreement with a large number of in vitro expression studies 
demonstrating biochemical and physiological interactions between the two proteins [32]. 
Ronzaud et al. [100] generated doxycycline-inducible, nephron-specific Nedd4L KO mice. 
Under standard and high sodium diets, conditional KO mice displayed decreased plasma 
aldosterone but normal Na/K balance. Under a high sodium diet, KO mice exhibited 
hypercalciuria and increased blood pressure, which were reversed by thiazide (but not amiloride 
treatment). Unlike the constitutive germ line model by Shi et al. [99]  the results demonstrate 
that loss of NEDD4-2 in adult renal tubules causes a new form of mild, salt-sensitive 
hypertension without hyperkalemia that is characterized by upregulation of NCC, elevation of 
βγ ENaC, but not α ENaC, and a normal Na/K balance maintained by downregulation of ENaC 
activity and upregulation of ROMK, a phenotype approaching more  that of a PHA II than a 
Liddle syndrome. The reasons for this difference may be due to one or a combination of the 
following factors i) the constitutive “chronic” deletion Nedd4L in all organs and tissues could 
trigger a number of compensatory mechanisms that could contribute to the Liddle-like 
phenotype;  ii) the “acute” deletion (within two weeks) of Nedd4-2 exclusively in the nephron 
could trigger different compensatory mechanisms and unmask an unexpected but interesting 
PHA II (normokalemic) phenotype demonstrating that Nedd4-2 might not only control ENaC 
activity but also NCC; iii) despite of the fact that in the two studies the same floxed allele was 
used (inactivation of exon 6 to 8), differences in genetic background and/or recombination 
efficiency in adult versus embryo could be one of the uncontrolled factor of this kind of 
experiment; iv) the generation of tissue specific spliced variant at N terminal start could also be 
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a confounding factor. Along this line, two other Nedd4L knockout models have been reported. 
Boase et al.  generated a total knockout of Nedd4L by inactivating Exon 15 and Kimura et al. 
[101] a lung-specific KO of exon 15 and downstream regions of the HECT (catalytic) domain to 
avoid possible splicing around the N-terminal start site. Boase et al. [102] observed increased 
ENaC activity and partial lethality due to premature lung fluid clearing.  Kimura et al. reported 
the development of a cystic fibrosis-like lung disease, with airway mucus obstruction, goblet cell 
hyperplasia, massive inflammation, fibrosis, and death by three weeks of age. These effects of 
Nedd4L loss are likely caused by enhanced ENaC function as described in cystic fibrosis. The 
lung defects were rescued with administration of amiloride into the lungs of young knockout 
pups via nasal instillation [101]. This is the first demonstration that ENaC activity in the lung is 
controlled by E3 ubiquitylation. These lung phenotype(s) were not observed in the original  
model of Shi et al., the major difference being the targeted allele. 
USP2-45  (Ubiquitin Specific Peptidase2-45)  
The deubiquitylation (DUB) enzyme USP2-45 is an aldosterone early induced gene [103, 104] 
and was identified in the kidney of animal stimulated by aldosterone for 30 minutes. USP2-45 is 
also cycling according to a circadian rhythm. Based on in vitro experiment [105-107], It was 
proposed that the effect of aldosterone on the deubiquitylation of ENaC could be synergistic 
with the effect of Sgk1 on Nedd4-2 whereas another study suggested that USP2-45 might down 
regulate the aldosterone response by interacting with the mineralocorticoid receptor [108]. 
Recently, Pouly et al [109] investigated the effect of Usp2 gene inactivation. USP2-45 protein 
has a rhythmic expression with a peak at ZT12. Usp2-KO mice did not show any differences to 
wild-type littermates with respect to the diurnal control of Na or K urinary excretion and plasma 
levels neither on standard diet, nor after acute and chronic changes to low and high Na+ diets, 
respectively. Moreover, they had similar aldosterone levels either at low or high Na+ diet. Blood 
pressure measurements using telemetry did not reveal variations as compared to control mice. 
The authors suggest that USP2 does not play a primary role in the control of Na+ balance or 
blood pressure [109]. One interpretation of these negative results is redundancy between DUBs 
and or interactions with other compensatory mechanisms.  
TSC22D3 (TSC22 domain family, member 3  or GILZ) 
As annotated, the protein encoded by this gene shares significant sequence identity with the 
murine TSC-22 and Drosophila shs, both of which are leucine zipper proteins, that function as 
transcriptional regulators. The expression of this gene is stimulated by glucocorticoids and 
interleukin 10, and it appears to play a key role in the anti-inflammatory and immunosuppressive 
effects of this steroid and chemokine.  
GILZ was identified in the transcriptome of a kidney cell line stimulated by aldosterone [110]. In 
an in vivo rat model, Muller et al. [111] showed that the Induction of GILZ may play a permissive 
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role in the enhancement of the early and/or late responses; these effects may be necessary for 
a full response but do not by themselves promote early changes in urinary sodium and 
potassium excretion. 
Suarez et al. [112] used Cre/loxP technology to generate mice deficient for Tsc22d3-2. Male 
knockout mice were viable but surprisingly did not show any major deficiencies in 
immunological processes or inflammatory responses. Tsc22d3-2 knockout mice adapted to a 
sodium-deprived diet and to water deprivation conditions but developed a subtle deficiency in 
renal sodium and water handling but, unexpectidely,the analysis of the Tsc22d3-2-deficient 
mice demonstrated a previously uncharacterized function of glucocorticoid-induced leucine 
zipper protein in testis development [112]. 
 
Conclusions and Perspectives 
 
 The genetic dissection of sodium and potassium transport along the ASDN allowed to 
define the most important limiting factors (transporters,hormone receptors, kinases, 
ubiquitylase) that are involved in the aldosterone- and angiotensin- dependent signaling 
pathways specifically expressed in the kidney. These limiting factors are, by definition, good 
candidate as drug targets for the treatment of hypertension. For example, ROMK, BK, Nedd4-2, 
WNK1, WNK4, Cullin 3, Kelch like 3, SPAK, ClCK/barttin, pendrin, SLC4A8 and to some extent 
Sgk1 are potential receptors for the development of new antihypertensive drugs. Conversely 
genetic evidence in transgenic mouse model indicate that Usp2-45 or GILZ are not limiting and 
thus not good potential drug targets.  
 The genetic dissection has also helped to begin to understand the molecular 
mechanisms underlying the « aldosterone paradox » (see recent reviews in references [115, 
116]. Aldosterone promotes different and somewhat opposed effects either in promoting 
potassium secretion (with minimun sodium retention) in case of hyperkalaemia or in promoting 
sodium reabsorption (with minimum potassium loss) in case of hypovolemia.  WNK4 
phosphorylation has been proposed as potential molecular switch [67]. It is likely, however, that 
other molecular switches will soon be discovered (MR phosphorylation ? E3 enzyme 
phophorylation ?) and thus defining two separate phoshorylation states of the signaling 
cascade(s) triggered by either aldosterone or angiotensin that could explain the aldosterone 
paradox. This would be a significant step for the successful development of the next generation 
diuretics that should have the following characteristics : i) block synergistically ENaC and NCC; 
ii) no change in efficacy in presence of high salt intake; iii) no effect on potassium balance (no 
hypo- or hyper- kalemia). These ideal diuretics would qualify for the name of anti-salt pill.  As 
shown in the ALLHAT study [117],  the present diuretics specially the thiazides were 
unsurpassed in long-term drug adherence, controlling elevated blood pressure and were 
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superior to other therapies in preventing one or more forms of cardiovascular events, having 
lower drug cost. Thiazides, however, have still significant side effects i.e. no control of 
potassium balance (hypokalemia and metabolic alkalosis), Type 2 diabetes and hyperuricemia. 
To minimize the side effects of an anti-salt pill, the following criteria should be met: i) 
pharmacodynamically, the anti salt pill should bind to its receptor with stereospecific, very high 
affinity (nM range), have high selectivity (no cross reactivity with related gene products), display 
nephron segment/tubular or cell specific expression of the receptor; ii) pharmacokinetically, the 
aim would be to maximally increase urinary apical  drug concentrations in ASDN for instance by 
active secretion of the drug by the proximal tubule. 
 What are the future developments that could contribute to our knowledge of ASDN function? 
The present mouse models have obvious limitations: i) despite of the fact that RAAS seem to 
operate to a great extent similarly in mouse and humans, the fine regulation of blood pressure is 
different (heart rate of 500 beats/min!); ii) in in most mouse models, the precise mutation(s) 
observed in human disease were often not introduced in the mouse genome due to 
methodological difficulties; iii) the cardiovascular phenotyping of the mouse remains 
challenging; iv) some pathologies (for instance nephrotic syndrome) are difficult to reproduce in 
mouse but possible in rats. Before the introduction of transgenic mouse models, the best 
characterised animal model for renal physiology and pathophysiology was the rat. The recent 
development of the zinc finger technology should allow, in a near future, to obtain transgenic rat 
models that could be useful for drug development. 
Finally, due to space limitations, important signaling pathways contributing significantly to the 
control of blood pressure could not be discussed here but should also be considered as a 
source of novel drug targets for the treatment of hypertension : circadian rthythm [118, 119],  
insulin [120], vasopressin [121, 122], endothelin [123], ANP [124, 125], TGFβ [126] to mention 
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Legend to Figure 1 
Model of a nephron, the functional unit of the kidney. 
The nephron is composed of a filtering apparatus the Glomerulus (G) (1), the proximal tubule 
(Proximal Convoluted Tubule (PCT)(2) and Proximal Straight Tubule (PST)(3), the Henle’s loop 
(Thin descending Limb (TL) (4) and Thick Ascending Limb (TAL) (5)), the Distal Convoluted 
Tubule (DCT)(6), the Connecting Tubule (CNT)(7). 10 to 12 nephrons branch on one Collecting 
Duct (CD) (8 to 11) made of the Cortical Collecting Duct (CCD), Outer medullaray Colecting 
Duct (OMCD) and the Inner Medullary Collecting Duct (IMCD). Adapted from Kritz and Kaissling 
[127]   
In human, 180 liters of fluid is filtered per day  through the glomerulus (G). Around 60% of the 
filtrate will be reabsorbed in the proximal tubule (PCT and PST) (2),30% in the Henle’s loop (TL 
and TAL) (4), 9% in DCT, CNT and CD leaving 1.8 liter/day of final urine. Over 90% of renal 
ATP is used for fluid reabsorption drivent by the Na,K-ATPase. Sodium and potassium balance 
are achieved through the final regulation of sodium and potassium transport in the distal 
nephron and the collecting duct under hormonal control (aldosterone, vasopressin,angiotensin, 
etc). DCT cells, CNT cells and CD principal cells are the main cells involved in hormonal 
regulation.  See for details linear model in Figure 2    
 
 
Legend to Figure 2 
Linear model of the distal nephron and collecting duct. 
The distal nephron is composed of the Straight Distal Tubule or Thick Asending Limb (TAL), the 
distal convoluted tubule (DCT1 and DCT2, the connectiong tubule (CNT) and the collecting duct 
(CD). The Aldosterone sensitive Distal Nephron (ASDN) is composet of DCT2, CNT and CD 
that co express 11bHSD2 and MR. The corresponding cells (TAL cells, DCT celles, CNT celles, 
CCD cells are shown above tehier corresponding nephron segments (drawings adapted from 
Kritz an Kaissling [127]. The nephron segment/cell specificexpression of the relevant 
transporters and the aldo and angiotensin dependent siganling pathways are shown (see text 
for discussion)   	  	  	  
Table 1 Phenotype of transgenic mouse models mimicking salt- retaining and salt- losing phenotypes along the distal 





Mouse gene Mouse Phenotype Ref 
SLC12A2 Bartter  
 type I 
Slc12a2 
Null allele 
Bartter I-like :severe extracellular volume depletion, hyperkalaemia, metabolic acidosis, 
hydronephrosis, and high plasma renin and aldosterone concentrations.   
[12] 




Bartter II -like :ROMK-deficient mice exhibit polyuria, natriuresis, and kaliuresis similar to individuals 
with type II antenatal Bartter syndrome 
[13] 
[45] 




The mouse phenotype is distinct from that Bartter III : overt nephrogenic diabetes insipidus with a 
decrease of approximately 27% in body weight. 
[14] 
[11] 






Bartter IV-like : Hypokalemia, metabolic alkalosis, and decreased NaCl reabsorption in distal tubules 




CASR Bartter  
Type V 
 









 Gitelman-like : subtle perturbations of sodium and fluid volume homeostasis, but renal handling of 
Mg2+ and Ca2+ are altered, as observed in Gitelman's syndrome. 
[48] 




 Systemic PHA 1 like : Severe PHA-1 phenotype with100% perinatal lethality [19] 




PHA-1 like : Severe PHA-1 phenotype with100% perinatal lethality [20] 




PHA-1 like : Severe PHA-1 phenotype with100% perinatal lethality [21] 
SCNN1A  Scnn1a lox/lox No phenotype [49] 
SCNN1A  Scnn1a lox/lox 
Hoxb7Cre 
No phenotype as far as sodium and potassium balance 
Full protection against lithium induced NDI 
[22] 
[23] 
SCNN1A  Scnn1a lox/lox 
Aqp2Cre 
Mild PHA-1 phenotype in adult mice 
 
[24] 
SCNN1A  Scn1a 
lox/loxPAX8 
rtTA/LC1 
Severe renal PHA-1 phenotype with salt loosing syndrome and 

















Disorders observed in BKa1, BKb1 or BKb4 KO mice have shed new insights on the importance of 




Slc26a4 Aldosterone and angiotensin II modulate the renal regulation of blood pressure, in part, by regulating 
pendrin-mediated Cl- absorption and ENaC-mediated Na+ absorption. 
[38, 39, 41, 
42] 
SLC4A8 no human 
disease 
Slc4a8 Evidence for a novel electroneutral, amiloride-resistant, thiazide-sensitive, transepithelial NaCl 
absorption in mouse CCDs, which persists even with genetic disruption of ENaC 
[37, 40, 42] 
 	  
  
Table 2 Phenotype of trangenic mouse models mimicking salt – retaining and salt- losing phenotypes along the distal nephron (TAL, DCT,CNT) and 
collecting duct (CD) :Aldosterone and Angiotensin dependent signaling pathways 
Human gene Human 
disease 







Barrter-like : intracellular trafficking of SPAK by the sorting receptor SORLA (i.e Sorl1) is 
critical for proper NKCC2 activation 
[52] 





 Ren 1c null 
Ren 2 null 
Hypotensive phenotype in females 
No BP phenotype 
[58] 
[57] 
AGT  Agt  
Null allele 
Profound hypotension in angiotensinogen-deficient mice demonstrates an indispensable role 
for the renin-angiotensin system in maintaining BP 
[60] 
[61] 
ACE  Ace  
Null allele 
 Heterozygous males but not females low blood pressures although both male and female 




 Agtr1a  
null allele 
Angiotensin II receptor Type 1 gene ablation 
Hypotensive phenotype and resistance to Angiotensin II administration 
[64] 
  Kidney cross 
transplantation 
Critical role of the kidney in the pathogenesis of hypertension and its cardiovascular 
complications.  Evidence supporting Guyton’s hypothesis 
[113] 
   Targeting Agtr1a receptor of the proximal tubule of the kidney decreases BP and could be a 
useful therapeutic strategy in hypertension. 
[66] 
WNK4  Wnk4 
hypomorphic 
 
Gitelman-like Salt loosing hypotensive phenotype : wt WNK4 is proposed to be a positive 





 Stk 39/SPAK 
Disruption of exon 
9 and 10 
Gitelman-like :Stk39/SPAK-null mice have defects of NCC in the kidneys and NKCC1 in the 
blood vessels, leading to hypotension through renal salt wasting and vasodilation.  
[71] 
  Stk39/SPAK 
kinase-dead ki 
SPAK plays an important role in controlling blood pressure in mammals. SPAK inhibitors 








PHAII like : Wnk4 is proposed to be a molecular switch that regulates the balance between 
NaCl reabsorption and K+ secretion 
[69] 
WNK4 PHAII Knock in 
Wnk4 D56A/+ 
PHAII like : WNK4 mutant activates NCC through activation OSR1-SPAK-NCC 
phosphorylation cascade. 
[70] 
WNK1  KS-Wnk1 -/- PHAII like : mild intermediate phenotype [74] 
CUL3 
KLHL3 
PHAII Cullin 3 
Kelch-like 3 
No mouse model reported. [76, 77] 
NR3C2 PHA-1  Nrc32 null allele PHA-1 like (renal) :  high perinatal lethality but rescued by saline infusion  [81] 
[82] 
NR3C2  Nrc32 
 
DCT2 and early CNT can compensate to a large extent deficient ENaC-mediated sodium 
reabsorption in late CNT and CD. 
[83] 
 
NR3C2  Nrc32 Under a low-salt, tamoxifen induced ablation of MR at the adult stage recapitulates the renal 
sodium wasting observed in mice with constitutive early-onset MR ablation.  
[84] 
NR3C2 (S810L) MR gain of 
function 
 No mouse model reported. Salt sensitive hypertension exarcebated during pregnancy [85] 
 Cushing  Cushing-like ACTH induced hypertension involves both MR and GR 
 
[86] 
HSD11B2 AME Hsdb2 Renal sodium retention remains a key event in apparent mineralocorticoid excess (AME) but 
that the accompanying hypertension changes from a renal to a vascular etiology over time. 
[89] 
11BHSD 2  Hsdb2 Salt sensitive hypertension is mediated by complex interactions between MR and GR in 
haploid insufficient mice 
 
[90] 
SGK1  Sgk1 Mild PHA-like phenotype under salt restriction 
Slight protection against DOCP induced hypertension. Overall, Sgk1 is not absolutely 




  Sgk1 Nephron specific inducible deletion in adult animals generates a mild PHA-1 phenotype under 
salt restiction together with low blood pressure 
[97] 
NEDD4L  Nedd4l 
Exon 7-9 
Salt-, amiloride- sensitive hypertension mimicking many features of Liddle syndrome 
No lung phenotype 
[99] 
  Nedd4l 
Exon 7-9 
Nephron specific inducible deletion in adult animals generate a novel mild salt sesnitive 
thiazide- sensitive, amiloride-insensitive hypertension mimicking some features of PHAII  
[101] 
  Nedd4l 
Exon 15 
Lung specific deletion generates a CFTR like phenotype [100] 
  Nedd4l 
Exon 15 
Constitutive germ line KO : severe respiratory distress and perinatal lethality in Nedd4-2-
deficient mice 
[102] 
USP2-45  Usp2-45 USP2 does not play a primary role in the control of sodium balance or blood pressure [109] 
TSC22D3  Tsc22d3 
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